Latest Press Releases
Read the latest official press releases and stock market announcements from Meyka.
MOBVISTA'S XMP AND ADSPOLAR BECOME META ADTECH BUSINESS PARTNERS
SINGAPORE--(BUSINESS WIRE)--NEW PARTNERSHIP UNLOCKS ADVANCED TOOLS, EARLY ACCESS TO META TRAFFIC, AND EXPERT SUPPORT TO DRIVE CLIENT GROWTH WORLDWIDE.
XPOVIO® (SELINEXOR) APPROVED FOR COMMERCIALIZATION IN INDONESIA, FURTHER EXPANDING ANTENGENE'S COMMERCIAL PRESENCE IN APAC
- XPOVIO ® IS THE FIRST AND ONLY APPROVED XPO1 INHIBITOR IN INDONESIA. - FROM THE SECOND HALF OF 2024 TO NOW, XPOVIO ® WAS SUCCESSIVELY APPROVED IN THAILAND, MALAYSIA AND INDONESIA, SIGNIFICANTLY EXPANDING ANTENGENE'S COMMERCIAL PRESENCE IN APAC.
ANTENGENE ANNOUNCES XPOVIO® APPROVED FOR PUBLIC HEALTH INSURANCE COVERAGE IN TAIWAN MARKET, BENEFITING MORE PATIENTS WITH R/R MM IN THE REGION
XPOVIO® IS THE FIRST XPO1 INHIBITOR APPROVED IN TAIWAN FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM). AFTER THE MAINLAND OF CHINA, SOUTH KOREA, AUSTRALIA AND SINGAPORE, TAIWAN MARKET IS THE FIFTH APAC MARKET IN WHICH XPOVIO® HAS BEEN APPROVED FOR PUBLIC HEALTH INSURANCE COVERAGE.
ANTENGENE TO PRESENT RESULTS FROM TWO LATE-STAGE STUDIES OF SELINEXOR SIGNALING POTENTIAL CLINICAL BREAKTHROUGH AT ASH 2024
SHANGHAI AND HONG KONG , NOV. 5, 2024 /PRNEWSWIRE/ -- ANTENGENE CORPORATION LIMITED ("ANTENGENE", SEHK: 6996.HK), A LEADING INNOVATIVE, COMMERCIAL-STAGE GLOBAL BIOPHARMACEUTICAL COMPANY DEDICATED TO DISCOVERING, DEVELOPING AND COMMERCIALIZING FIRST-IN-CLASS AND/OR BEST-IN-CLASS MEDICINES FOR CANCER, TODAY ANNOUNCED THAT IT WILL PRESENT THE LATEST DATA FROM TWO CLINICAL STUDIES OF SELINEXOR IN TWO POSTERS AT THE 2024 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING (ASH 2024), TAKING PLACE ON DECEMBER 7-10, 2024, IN SAN DIEGO, CA, THE UNITED STATES. DETAILS ON THE POSTERS: TITLE: WEEKLY SELINEXOR, BORTIZOMIB AND DEXAMETHASONE (SVD) VERSUS TWICE WEEKLY BORTIZOMIB AND DEXAMETHASONE (VD) IN CHINESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): PRIMARY ANALYSIS OF PHASE III BENCH STUDY PUBLICATION NUMBER: 4748 SESSION: 654.
ANTENGENE ANNOUNCES XPOVIO® (SELINEXOR) APPROVED FOR ITS THIRD INDICATION IN SOUTH KOREA, BRINGING FRESH HOPE TO PATIENTS WITH MM IN THE COUNTRY
THIS APPROVAL FOR XPOVIO® FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA (MM) MARKS THE THIRD APPROVED INDICATION OF THE DRUG IN SOUTH KOREA. TO DATE, XPOVIO® HAS ALREADY BEEN INCLUDED IN NATIONAL HEALTH INSURANCE OR REIMBURSEMENT SCHEMES IN SOUTH KOREA, THE MAINLAND OF CHINA, AUSTRALIA AND SINGAPORE, AND IS EXPECTED TO ACHIEVE NATIONAL REIMBURSEMENT COVERAGE IN MORE APAC MARKETS.
ANTENGENE ANNOUNCES XPOVIO® (SELINEXOR) APPROVED FOR COMMERCIALIZATION IN THAILAND
XPOVIO® IS THE FIRST AND ONLY APPROVED XPO1 INHIBITOR IN THAILAND. XPOVIO® HAS BEEN APPROVED FOR MULTIPLE INDICATIONS IN NINE MARKETS ACROSS THE APAC REGION.
ANTENGENE ANNOUNCES XPOVIO® (SELINEXOR) APPROVED FOR COMMERCIALIZATION IN MALAYSIA
XPOVIO® IS THE FIRST AND ONLY APPROVED XPO1 INHIBITOR IN MALAYSIA. XPOVIO® HAS BEEN APPROVED FOR MULTIPLE INDICATIONS IN EIGHT MARKETS ACROSS THE APAC REGION.
ANTENGENE ANNOUNCES XPOVIO® (SELINEXOR) NATIONAL HEALTH INSURANCE SERVICE APPROVAL FOR REIMBURSEMENT IN SOUTH KOREA
- XPOVIO® IS THE FIRST XPO1 INHIBITOR APPROVED FOR REIMBURSEMENT BY SOUTH KOREA'S NATIONAL HEALTH INSURANCE SERVICE (NHIS) FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM). - THE APPROVAL OF XPOVIO® BY THE NHIS IN SOUTH KOREA IS THE FOURTH NATIONAL REIMBURSEMENT IN THE ANTENGENE MARKETS AFTER MAINLAND OF CHINA, AUSTRALIA AND SINGAPORE.